Semax (20 mg Vial) Dosage Protocol

Dosing & Reconstitution Overview

Semax is a short synthetic peptide derived from the ACTH(4–10) sequence with an added C-terminal Pro-Gly-Pro tail that slows enzymatic breakdown. The numbers below are assembled strictly for laboratory and educational reference — they describe how the compound has been handled and measured in published work, not a recommendation for use in humans or animals.

For a 20 mg vial, adding 4.0 mL of bacteriostatic water yields a concentration of 5 mg/mL (5,000 mcg/mL). At that concentration each insulin-syringe unit (0.01 mL) carries 50 mcg, so 0.10 mL equals 10 units and delivers 500 mcg. That ratio keeps the titration arithmetic in clean 50 mcg increments.

Standard (Gradual) Titration Schedule

The gradual schedule follows the slow step-up pattern reported in the nootropic literature, where the daily amount is raised every couple of weeks while tolerability at each level is confirmed.

Reconstitution Steps

1. Let the sealed lyophilized vial and the bacteriostatic water reach room temperature, then wipe both stoppers with an alcohol swab.
2. Draw 4.0 mL of bacteriostatic water and inject it slowly down the inside wall of the vial — never directly onto the powder pellet.
3. Swirl gently until fully dissolved. Do not shake; vigorous agitation can damage the peptide.
4. The solution should be clear and colourless. Label the vial with the concentration (5 mg/mL) and the reconstitution date.
5. Store upright under refrigeration between uses and draw each subsequent volume with a fresh sterile syringe.

Advanced (Aggressive) Titration Schedule

The advanced schedule reaches the upper bound of the research band more quickly, holding each level for a single week before escalating to the 800 mcg ceiling reported in the literature.

Supplies Needed

• Semax vials (20 mg): one vial covers a full 8-week gradual cycle; ~2 vials if running back-to-back cycles or sustained 800 mcg daily.
• Insulin syringes (U-100, 1 mL): ~56 for an 8-week daily schedule (one fresh syringe per draw).
• Bacteriostatic water (10 mL): one bottle reconstitutes two 20 mg vials with room to spare.
• Alcohol swabs: a single 100-count box comfortably covers an 8-week schedule.

Protocol Overview

• Research goal: model cognitive and neuroprotective signalling via the ACTH(4–10) fragment and BDNF modulation.
• Schedule: once-daily subcutaneous administration in the injectable model (intranasal is the more common clinical route).
• Dose band: 300–800 mcg daily.
• Fill: 20 mg lyophilized, reconstituted to 5 mg/mL with 4 mL diluent.
• Storage: −20 °C dry; 2–8 °C once reconstituted.

Dosing Protocol Notes

• Begin at the lowest 300 mcg step and hold each level before stepping up.
• Keep administration on a fixed daily cadence, ideally earlier in the day, for steady exposure modelling.
• Escalate only after tolerability is established at the prior step.
• Cycle conventions in the literature typically run multi-week courses rather than continuous indefinite use.

Storage Instructions

Keep sealed lyophilized vials at −20 °C, protected from light, where stability extends for many months. Once reconstituted, refrigerate at 2–8 °C and use within about 30 days. Allow refrigerated solution to warm slightly before drawing, avoid repeated freeze-thaw cycles, and aliquot if a vial will be sampled many times.

Important Handling Notes

• Use a sterile syringe for every draw and never re-enter the vial with a used needle.
• Rotate sampling/handling technique to keep the stopper intact.
• Because the working volumes are small (6–16 units), measure carefully on a U-100 scale.
• Document each draw — date, volume, remaining material — for reproducibility.

How Semax Works

Semax is a synthetic heptapeptide built on the ACTH(4–10) fragment with a Pro-Gly-Pro tripeptide added at the C-terminus to resist peptidase cleavage. Unlike the parent ACTH sequence, it lacks meaningful corticotropic activity, so it does not drive cortisol release. In published models it is reported to raise brain-derived neurotrophic factor (BDNF) expression and to enhance cholinergic and dopaminergic signalling, alongside antioxidant and neuroprotective effects. These mechanisms underpin its study as a nootropic and as a candidate in cerebrovascular and optic-nerve injury research.

Reported Benefits & Side Effects

Benefits observed in studies

• Reported support for attention, memory consolidation and learning in clinical populations.
• Investigated for recovery support in ischemic stroke and traumatic brain injury.
• Studied in glaucomatous and ischemic optic neuropathy with favourable safety reports.
• No significant rise in cortisol or other adverse endocrine signals noted in human studies.

Side effects reported

• Minor nasal irritation when delivered intranasally.
• Mild injection-site reactions such as redness or itching with the subcutaneous route.
• Overall the published safety profile is described as benign across the studied dose range.

Supporting Lifestyle Factors (Research Context)

• Adequate sleep, which is closely tied to the memory-consolidation endpoints in cognitive studies.
• Cognitive engagement (learning tasks) used as the measured context in nootropic research designs.
• Stable hydration and nutrition as standard study controls.

Injection Technique (Reference Only)

• Prepare the vial and site with alcohol swabs and let them dry.
• Insert subcutaneously at a 45–90° angle depending on needle length; aspiration is not required for subcutaneous work.
• Because doses are small, draw slowly and tap out air to keep the unit reading accurate.
• Rotate sites systematically and dispose of sharps in an approved container.

References

Related Protocols